1063 related articles for article (PubMed ID: 16303268)
1. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Owens DE; Peppas NA
Int J Pharm; 2006 Jan; 307(1):93-102. PubMed ID: 16303268
[TBL] [Abstract][Full Text] [Related]
2. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
[TBL] [Abstract][Full Text] [Related]
3. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
Huang M; Wu W; Qian J; Wan DJ; Wei XL; Zhu JH
Acta Pharmacol Sin; 2005 Dec; 26(12):1512-8. PubMed ID: 16297352
[TBL] [Abstract][Full Text] [Related]
4. Shielding Therapeutic Drug Carriers from the Mononuclear Phagocyte System: A Review.
Sathyamoorthy N; Dhanaraju MD
Crit Rev Ther Drug Carrier Syst; 2016; 33(6):489-567. PubMed ID: 27992308
[TBL] [Abstract][Full Text] [Related]
5. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles.
Shan X; Yuan Y; Liu C; Tao X; Sheng Y; Xu F
Biomed Microdevices; 2009 Dec; 11(6):1187-94. PubMed ID: 19609680
[TBL] [Abstract][Full Text] [Related]
6. Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles.
Gaucher G; Asahina K; Wang J; Leroux JC
Biomacromolecules; 2009 Feb; 10(2):408-16. PubMed ID: 19133718
[TBL] [Abstract][Full Text] [Related]
7. In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer.
Shan X; Liu C; Yuan Y; Xu F; Tao X; Sheng Y; Zhou H
Colloids Surf B Biointerfaces; 2009 Sep; 72(2):303-11. PubMed ID: 19450955
[TBL] [Abstract][Full Text] [Related]
8. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable nanoparticles of amphiphilic triblock copolymers based on poly(3-hydroxybutyrate) and poly(ethylene glycol) as drug carriers.
Chen C; Yu CH; Cheng YC; Yu PH; Cheung MK
Biomaterials; 2006 Sep; 27(27):4804-14. PubMed ID: 16740306
[TBL] [Abstract][Full Text] [Related]
10. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan.
Sheng Y; Liu C; Yuan Y; Tao X; Yang F; Shan X; Zhou H; Xu F
Biomaterials; 2009 Apr; 30(12):2340-8. PubMed ID: 19150737
[TBL] [Abstract][Full Text] [Related]
11. Stable stealth function for hollow polyelectrolyte microcapsules through a poly(ethylene glycol) grafted polyelectrolyte adlayer.
Wattendorf U; Kreft O; Textor M; Sukhorukov GB; Merkle HP
Biomacromolecules; 2008 Jan; 9(1):100-8. PubMed ID: 18078322
[TBL] [Abstract][Full Text] [Related]
12. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol).
Zahr AS; Davis CA; Pishko MV
Langmuir; 2006 Sep; 22(19):8178-85. PubMed ID: 16952259
[TBL] [Abstract][Full Text] [Related]
13. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
Sant S; Poulin S; Hildgen P
J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
[TBL] [Abstract][Full Text] [Related]
14. Surface-functionalized nanoparticles for controlled drug delivery.
Choi SW; Kim WS; Kim JH
Methods Mol Biol; 2005; 303():121-31. PubMed ID: 15923680
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation.
Rabanel JM; Hildgen P; Banquy X
J Control Release; 2014 Jul; 185():71-87. PubMed ID: 24768790
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate.
Ishihara T; Kubota T; Choi T; Higaki M
J Pharmacol Exp Ther; 2009 May; 329(2):412-7. PubMed ID: 19244548
[TBL] [Abstract][Full Text] [Related]
17. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles.
Garcia-Fuentes M; Torres D; MartÃn-Pastor M; Alonso MJ
Langmuir; 2004 Sep; 20(20):8839-45. PubMed ID: 15379515
[TBL] [Abstract][Full Text] [Related]
18. PEGylated nanocarriers for systemic delivery.
Jain NK; Nahar M
Methods Mol Biol; 2010; 624():221-34. PubMed ID: 20217599
[TBL] [Abstract][Full Text] [Related]
19. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro.
Gou M; Zheng L; Peng X; Men K; Zheng X; Zeng S; Guo G; Luo F; Zhao X; Chen L; Wei Y; Qian Z
Int J Pharm; 2009 Jun; 375(1-2):170-6. PubMed ID: 19427143
[TBL] [Abstract][Full Text] [Related]
20. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone.
Choi SW; Kim JH
J Control Release; 2007 Sep; 122(1):24-30. PubMed ID: 17628158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
